Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

In the latest trading session, Invitae (NVTA) closed at $29.95, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.74% gain on the day. Coming into today, shares of the ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where Invitae Corporation (OTC:NVTAQ) stands ...

Invitae (NYSE:NVTA) stock popped on investors’ radars earlier this month thanks to its nearly 277% surge in price on Aug 10. Following its latest earnings report, retail traders jumped into the stock ...

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Invitae’s revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability. Invitae shares have dropped more than ...